The company believes that Xdrop will find adopters in academia and clinical research, although diagnostics is on its radar.
In Nature this week: circular consensus sequencing method to sequence and assemble a human genome, a new CRISPR platform using the Cpf1 endonuclease, and more.
The firm reported total revenues of $24.6 million, with $21.3 million in product revenue, and expects its acquisition by Illumina to be completed in Q4 2019.
The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.
The patent, EP3170904, "Compositions and methods for nucleic acid sequencing," is the second PacBio patent revoked by the EPO this year.
As expected, the UK's Competition and Markets Authority is referring the proposed Illumina acquisition of PacBio for an in-depth Phase 2 investigation.
Flye and wtdbg2, both released this year, work with Pacific Biosciences and Oxford Nanopore data and can assemble bacterial and more complex genomes.
The company recognized total first quarter revenues of $16.4 million and a net loss of $30.3 million.
The Competition and Markets Authority is in charge of promoting competition and reducing anti-competitive activities in the UK.
The study used a variety of sequencing and mapping technologies, including from Illumina, Pacific Biosciences, 10X Genomics, Bionano Genomics, and Oxford Nanopore.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.
The Los Angeles Times reports that only a third of California students meet the state's new science standards.
In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.